Norepinephrine Infusion During Cardiopulmonary Bypass

NACompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 6, 2020

Primary Completion Date

April 10, 2021

Study Completion Date

September 20, 2021

Conditions
Cardiac SurgeryCardiopulmonary Bypass
Interventions
DRUG

Placebo

Patients undergoing different cardiac surgical procedures will receive a continuous intravenous infusion of Normal Saline 0.9% with a starting dose of 0.0025 ml/kg/min.

DRUG

Norepinephrine

Patients undergoing different cardiac surgical procedures will receive a continuous intravenous infusion of norepinephrine (40 ug/ml) with a starting dose of 0.0025 ml/kg/min.

OTHER

Increase infusion rate

Infusion rate will be increased as needed in order to maintain a MAP ≥65 mmHg during cardiopulmonary bypass period as per the discretion of the anesthesiologist using 0.00125 ml/kg/min increments

OTHER

Decrease infusion rate

Infusion rate will be decreased as needed in order to maintain a MAP ≥65 mmHg during cardiopulmonary bypass period as per the discretion of the anesthesiologist using 0.00125 ml/kg/min decrements

Trial Locations (2)

31952

Dammam University, Khobar

Imam Abdulrahamn Bin Faisal University (Former, Dammam University), Dammam

All Listed Sponsors
lead

Imam Abdulrahman Bin Faisal University

OTHER

NCT04312971 - Norepinephrine Infusion During Cardiopulmonary Bypass | Biotech Hunter | Biotech Hunter